Surgery in Hemophilia. The General View: Patient Selection, Timing, and Preoperative Assessment

References 

1. Nilsson IM , Berntorp E , Löfqvist T , Pettersson H . Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B . J Intern Med . 1992;232:25–32
   • MEDLINE
   • CrossRef
2. Petrini P , Lindvall N , Egberg N , Blombäck M . Prophylaxis with factor concentrates in preventing hemophilic arthropathy . Am J Paediatr Hematol Oncol . 1991;13:280–287
3. Fischer K , van der Bom JG , Molho P , Negrier C , Mauser-Bunschoten EP , Roosendaal G , et al.  Prophylactic versus on-demand treatment strategies for severe haemophilia (A comparison of costs and long-term outcome) . Haemophilia . 2002;8:745–752
   • MEDLINE
4. Steen Carlsson K , Höjgård S , Glomstein A , Lethagen S , Schulman S , Tengborn L , et al.  On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden (Differences in treatment characteristics and outcome) . Haemophilia . 2003;9:555–566
   • MEDLINE
5. Sørensen B , Ingerslev J . Whole blood clot formation phenotypes in haemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa . J Thromb Haemost . 2004;2:102–110
   • MEDLINE
   • CrossRef
6. Tjønnfjord GE , Brinch L , Gedde-Dahl T , Brosstad FR . Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX . Haemophilia . 2004;10:174–178
   • MEDLINE
7. Ingerslev J . Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors . Semin Thromb Hemost . 2000;26:425–432
   • MEDLINE